Skip to main content
. 2017 Jan 4;292(6):2345–2358. doi: 10.1074/jbc.M116.764522

FIGURE 8.

FIGURE 8.

Ultrasound-targeted TRAF3IP2 AS-ODN attenuates I/R-induced myocardial injury-control studies. A, following 30 min ischemia, animals were administered with PESDA-encapsulated TRAF3IP2 AS-ODN with simultaneous application of therapeutic ultrasound. PESDA alone or PESDA-encapsulated scrambled ODN served as controls. Arrows indicate infarcted region. Although representative images are shown on the top, results from 6 to 8 mice/group are summarized in the bottom of panel A, †, p < 0.05 or ††, p < 0.01 versus I/R + PESDA alone (n = 6–8/group). B, TRAF3IP2 AS-ODN significantly inhibits TRAF3IP2 expression in heart, but not lung, liver, or kidney. A representative immunoblot (n = 2–4/group) showing TRAF3IP2 expression in various organs following 30 min ischemia/24 h reperfusion is shown. C and D, administration of scrambled AS-ODN or TRAF3IP2 AS-ODN had no effect on histology of non-cardiac organs or liver function. Lung, liver, and kidneys from animals administered with TRAF3IP2 AS-ODN were analyzed by H&E for histological changes. Scrambled ODN served as a control. Liver function (D) was analyzed by quantifying serum ALT and AST levels by ELISA.